Suppr超能文献

通过微调靶基因的mRNA结构在细胞质中高水平生产可溶性交叉反应物质197

High-Level Production of Soluble Cross-Reacting Material 197 in Cytoplasm Due to Fine Tuning of the Target Gene's mRNA Structure.

作者信息

Khodak Yulia Alexandrovna, Ryazanova Alexandra Yurievna, Vorobiev Ivan Ivanovich, Kovalchuk Alexander Leonidovich, Ovechko Nikolay Nikolaevich, Aparin Petr Gennadievich

机构信息

Federal State Institution, Federal Research Centre "Fundamentals of Biotechnology", The Russian Academy of Sciences, 119071 Moscow, Russia.

National Research Center, Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russia.

出版信息

BioTech (Basel). 2023 Jan 11;12(1):9. doi: 10.3390/biotech12010009.

Abstract

Cross-reacting material 197 (CRM197) is a non-toxic mutant of the diphtheria toxin and is widely used as a carrier protein in conjugate vaccines. This protein was first obtained from the supernatant of the mutant strain. This pathogenic bacteria strain is characterized by a slow growth rate and a relatively low target protein yield, resulting in high production costs for CRM197. Many attempts have been made to establish high-yield protocols for the heterologous expression of recombinant CRM197 in different host organisms. In the present work, a novel CRM197-producing strain was constructed. The target protein was expressed in the cytoplasm of SHuffle T7 cells without any additional tags and with a single potential mutation-an additional Met [-1]. The fine tuning of the mRNA structure (the disruption of the single hairpin in the start codon area) was sufficient to increase the CRM197 expression level several times, resulting in 150-270 mg/L (1.1-2.0 mg/g wet biomass) yields of pure CRM197 protein. Besides the high yield, the advantages of the obtained expression system include the absence of the necessity of CRM197 refolding or tag removal. Thus, an extensive analysis of the mRNA structure and the removal of the unwanted hairpins in the 5' area may significantly improve the target protein expression rate.

摘要

交叉反应物质197(CRM197)是白喉毒素的一种无毒突变体,在结合疫苗中广泛用作载体蛋白。这种蛋白质最初是从突变菌株的上清液中获得的。该病原菌菌株生长速度缓慢,目标蛋白产量相对较低,导致CRM197的生产成本较高。人们已经进行了许多尝试,以建立在不同宿主生物体中重组CRM197异源表达的高产方案。在本研究中,构建了一种新型的产生CRM197的菌株。目标蛋白在SHuffle T7细胞的细胞质中表达,没有任何额外的标签,并且有一个潜在的单一突变——额外的甲硫氨酸[-1]。对mRNA结构的微调(起始密码子区域单个发夹结构的破坏)足以将CRM197的表达水平提高几倍,从而产生150-270 mg/L(1.1-2.0 mg/g湿生物质)的纯CRM197蛋白产量。除了高产之外,所获得的表达系统的优点还包括无需对CRM197进行重折叠或去除标签。因此,对mRNA结构进行广泛分析并去除5'区域不需要的发夹结构可能会显著提高目标蛋白的表达率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac6/9844443/99933c8f0c24/biotech-12-00009-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验